Found: 49
Select item for more details and to access through your institution.
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 11, p. 2985, doi. 10.1007/s00432-021-03866-2
- By:
- Publication type:
- Article
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 9, p. 2437, doi. 10.1007/s00432-021-03782-5
- By:
- Publication type:
- Article
Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
- Published in:
- Japanese Journal of Clinical Oncology, 2024, v. 54, n. 3, p. 319, doi. 10.1093/jjco/hyad162
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 5, p. 1362, doi. 10.3390/jcm9051362
- By:
- Publication type:
- Article
Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 1, p. 102, doi. 10.3390/jcm9010102
- By:
- Publication type:
- Article
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 4, p. 450, doi. 10.3390/jcm8040450
- By:
- Publication type:
- Article
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1303543
- By:
- Publication type:
- Article
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 2, p. 291, doi. 10.1007/s10637-018-0656-z
- By:
- Publication type:
- Article
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920927841
- By:
- Publication type:
- Article
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 6, p. 1699, doi. 10.1007/s00262-023-03370-1
- By:
- Publication type:
- Article
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2024, v. 94, n. 2, p. 197, doi. 10.1007/s00280-024-04666-4
- By:
- Publication type:
- Article
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
- Published in:
- Cancers, 2024, v. 16, n. 17, p. 3037, doi. 10.3390/cancers16173037
- By:
- Publication type:
- Article
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 20, p. 4988, doi. 10.3390/cancers15204988
- By:
- Publication type:
- Article
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 17, p. 4358, doi. 10.3390/cancers15174358
- By:
- Publication type:
- Article
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1543, doi. 10.3390/cancers15051543
- By:
- Publication type:
- Article
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 410, doi. 10.3390/cancers11030410
- By:
- Publication type:
- Article
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 365, doi. 10.3390/cancers11030365
- By:
- Publication type:
- Article
Tumor Neovascularization and Developments in Therapeutics.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 316, doi. 10.3390/cancers11030316
- By:
- Publication type:
- Article
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.
- Published in:
- Cancers, 2019, v. 11, n. 3, p. 282, doi. 10.3390/cancers11030282
- By:
- Publication type:
- Article
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 7, p. e2322915, doi. 10.1001/jamanetworkopen.2023.22915
- By:
- Publication type:
- Article
Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 8, p. 9097, doi. 10.1002/cam4.5647
- By:
- Publication type:
- Article
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 4, p. 1521, doi. 10.1002/cam4.2037
- By:
- Publication type:
- Article
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.663612
- By:
- Publication type:
- Article
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.630136
- By:
- Publication type:
- Article
Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations.
- Published in:
- Proteomes, 2023, v. 11, n. 1, p. 6, doi. 10.3390/proteomes11010006
- By:
- Publication type:
- Article
Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study.
- Published in:
- Thoracic Cancer, 2022, v. 13, n. 2, p. 173, doi. 10.1111/1759-7714.14236
- By:
- Publication type:
- Article
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer.
- Published in:
- Thoracic Cancer, 2019, v. 10, n. 3, p. 526, doi. 10.1111/1759-7714.12969
- By:
- Publication type:
- Article
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis.
- Published in:
- International Journal of Oncology, 2020, v. 56, n. 3, p. 848, doi. 10.3892/ijo.2020.4969
- By:
- Publication type:
- Article
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-74573-0
- By:
- Publication type:
- Article
Recurrence of Large-Vessel Vasculitis Induced by Multiple Types of Granulocyte Colony-Stimulating Factor Preparation in Patient with Large-Cell Neuroendocrine Lung Carcinoma: A Case Report.
- Published in:
- Case Reports in Oncology, 2023, v. 16, n. 1, p. 771, doi. 10.1159/000533375
- By:
- Publication type:
- Article
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 2, p. 423, doi. 10.3390/diagnostics12020423
- By:
- Publication type:
- Article
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib.
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 12, p. 2170, doi. 10.3390/diagnostics11122170
- By:
- Publication type:
- Article
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 411, doi. 10.1007/s11523-024-01045-0
- By:
- Publication type:
- Article
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 6, p. 915, doi. 10.1007/s11523-023-01012-1
- By:
- Publication type:
- Article
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 657, doi. 10.1007/s11523-023-00991-5
- By:
- Publication type:
- Article
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non‐Small‐Cell Lung Cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. e681, doi. 10.1093/oncolo/oyae001
- By:
- Publication type:
- Article
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. 551, doi. 10.1093/oncolo/oyad013
- By:
- Publication type:
- Article
Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
- Published in:
- Oncologist, 2022, v. 27, n. 11, p. 903, doi. 10.1093/oncolo/oyac193
- By:
- Publication type:
- Article
Phase II Study of S‐1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. 1033, doi. 10.1634/theoncologist.2019-0290
- By:
- Publication type:
- Article
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. 459, doi. 10.1634/theoncologist.2018-0858
- By:
- Publication type:
- Article
Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade.
- Published in:
- Oncology Letters, 2019, v. 18, n. 2, p. 2140, doi. 10.3892/ol.2019.10466
- By:
- Publication type:
- Article
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1399889
- By:
- Publication type:
- Article
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1348034
- By:
- Publication type:
- Article
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum–Etoposide Chemotherapy.
- Published in:
- Drugs & Aging, 2023, v. 40, n. 6, p. 563, doi. 10.1007/s40266-023-01034-4
- By:
- Publication type:
- Article
High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib.
- Published in:
- Cancer Science, 2023, v. 114, n. 2, p. 606, doi. 10.1111/cas.15608
- By:
- Publication type:
- Article
Co-infection with Legionella and SARS-CoV-2: a case report.
- Published in:
- JA Clinical Reports, 2021, v. 7, n. 1, p. 1, doi. 10.1186/s40981-021-00467-3
- By:
- Publication type:
- Article
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
- Published in:
- Medical Oncology, 2020, v. 37, n. 12, p. 1, doi. 10.1007/s12032-020-01440-3
- By:
- Publication type:
- Article